Clinical Trials

79 enrolled

HER-2 Negative Breast Cancer

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

BreastGastrointestinalGynecologic

604 enrolled

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT05005403 2026-04-13

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

BreastGastrointestinalHead & NeckThoracic

694 enrolled

Anophthalmia with pulmonary hypoplasia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

BreastGastrointestinalThoracic

392 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT05579366 2026-04-07

RAINFOL-01

Phase 1/2 Recruiting

764 enrolled

BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05769010 2026-04-01

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

150 enrolled

Breast Neoplasms

NCT05806060 2026-03-25

BCTOP-T-M01

Phase 3 Recruiting

134 enrolled

Triple Negative Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

792 enrolled

Breast Neoplasms

NCT07446452 2026-03-03

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

37 enrolled

HER2-low Breast Cancer

NCT06976944 2026-02-23

PRELUDE

44 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07351487 2026-01-20

Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

37 enrolled

Triple Negative Breast Neoplasms

NCT06400472 2026-01-14

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors